Update on daptomycin: the first approved lipopeptide antibiotic

Bibliography

• JONES RN, CROCO MA, KUGLER KC et al.: Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn. Microbiol. Infect. Dis. (2000) 37:115-125.
   PubMedGoogle Scholar
• LEE SY, KUTI JL, NICOLAU DP: Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. (2005) 6:283-295.
   PubMedGoogle Scholar
• NNIS SYSTEM: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control (2003) 31:481-498.
   PubMed Web of Science ®Google Scholar
• FRIDKIN SK, HAGEMAN JC, MORRISON M et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. (2005) 352:1436-1444.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Staphylococcus aureus resistant to vancomycin – United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51:565-567.
   PubMedGoogle Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Vancomycin-resistant Staphylococcus aureus – New York, 2004. MMWR Morb. Mortal. Wkly Rep. (2004) 53:322-323.
   PubMedGoogle Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Vancomycin-resistant Staphylococcus aureus – Pennsylvania, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51:902.
   PubMedGoogle Scholar
• TALLY FP, ZECKEL M, WASILEWSKI MM et al.: Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs (1999) 8:1223-1238.
   PubMedGoogle Scholar
• TALLY FP, DEBRUIN MF: Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. (2000) 46:523-526.
   PubMed Web of Science ®Google Scholar
• SCHRIEVER CA, FERNANDEZ C, RODVOLD KA et al.: Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm. (2005) 62:1145-1158.
   PubMedGoogle Scholar
• GARRISON MW, ROTSCHAFER JC, CROSSLEY KB: Suboptimal effect of daptomycin in the treatment of bacteremias. South. Med. J. (1989) 82:1414-1415.
   Google Scholar
• RYBAK MJ, HERSHBERGER E, MOLDOVAN T et al.: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob. Agents Chemother. (2000) 44:1062-1066.
   PubMed Web of Science ®Google Scholar
• TEDESCO KL, RYBAK MJ: Daptomycin. Pharmacotherapy (2004) 24:41-57.
   PubMed Web of Science ®Google Scholar
• LAPLANTE KL, RYBAK MJ: Daptomycin – a novel antibiotic against Gram-positive pathogens. Expert Opin. Pharmacother. (2004) 5:2321-2331.
   PubMed Web of Science ®Google Scholar
• JEU L, FUNG HB: Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin. Ther. (2004) 26:1728-1757.
   PubMed Web of Science ®Google Scholar
• STEENBERGEN JN, ALDER J, THORNE GM et al.: Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. (2005) 55:283-288.
   PubMed Web of Science ®Google Scholar
• CARPENTER CF, CHAMBERS HF: Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. (2004) 38:994-1000.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JA, PERLMUTTER NG, SHAPIRO HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47:2538-2544.
   PubMed Web of Science ®Google Scholar
• CUBIST PHARMACEUTICALS, INC.: Cubicin (daptomycin) prescribing information. Cubist Pharmaceuticals, Inc., Lexington (MA) USA (2005).
   Google Scholar
• SILVERMAN JA: Progress towards understanding the molecular basis of daptomycin resistance. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2005).
   Google Scholar
• CANEPARI P, BOARETTI M, LLEO MM et al.: Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob. Agents Chemother. (1990) 34:1220-1226.
   PubMed Web of Science ®Google Scholar
• LAKEY JH, PTAK M: Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry (1988) 27:4639-4645.
   PubMed Web of Science ®Google Scholar
• WU M, MAIER E, BENZ R et al.: Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry (1999) 38:7235-7242.
   PubMed Web of Science ®Google Scholar
• MAGET-DANA R, PEYPOUX F: Iturins, a special class of pore-forming lipopeptides: biological and physicochemical properties. Toxicology (1994) 87:151-174.
   PubMed Web of Science ®Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. (2000) 38:51-58.
   PubMed Web of Science ®Google Scholar
• WISE R, ANDREWS JM, ASHBY JP: Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J. Antimicrob. Chemother. (2001) 48:563-567.
   PubMed Web of Science ®Google Scholar
• SNYDMAN DR, JACOBUS NV, MCDERMOTT LA et al.: Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2000) 44:3447-3450.
   PubMed Web of Science ®Google Scholar
• HANBERGER H, NILSSON LE, MALLER R et al.: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob. Agents Chemother. (1991) 35:1710-1716.
   PubMed Web of Science ®Google Scholar
• WOODWORTH JR, NYHART EH Jr, BRIER GL et al.: Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob. Agents Chemother. (1992) 36:318-325.
   PubMed Web of Science ®Google Scholar
• DVORCHIK BH, BRAZIER D, DEBRUIN MF et al.: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. (2003) 47:1318-1323.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ, BAILEY EM, LAMP KC et al.: Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for Gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. (1992) 36:1109-1114.
   PubMed Web of Science ®Google Scholar
• BENVENUTO M, BENZIGER D, YANKELEV S et al.: Safety and pharmacokinetics of daptomycin at doses up to 12 mg/kg daily. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2005).
   Google Scholar
• DVORCHIK B, ARBEIT RD, CHUNG J et al.: Population pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. (2004) 48:2799-2807.
   PubMed Web of Science ®Google Scholar
• DVORCHIK BH, SICA D, GEHR T: Pharmacokinetics and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2002) A-1387.
   Google Scholar
• DVORCHIK B: Moderate liver impairment has no influence on daptomycin pharmacokinetics. J. Clin. Pharmacol. (2004) 44:715-722.
   PubMed Web of Science ®Google Scholar
• DVORCHIK BH, DAMPHOUSSE D: The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J. Clin. Pharmacol. (2005) 45:48-56.
   PubMed Web of Science ®Google Scholar
• COTTAGNOUD P, PFISTER M, ACOSTA F et al.: Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. (2004) 48:3928-3933.
   PubMed Web of Science ®Google Scholar
• WISE R, GEE T, ANDREWS JM et al.: Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob. Agents Chemother. (2002) 46:31-33.
   PubMed Web of Science ®Google Scholar
• ALDER J, ARBEIT R, EISENSTEIN B: Pulmonary epithelial lining fluid (ELF) as a privileged site: daptomycin in pulmonary infections. Presented at the 11th International Congress of Infectious Diseases. Cancun, Mexico (2004) Abstr. 60.005.
   Google Scholar
• SILVERMAN JA, MORTIN LI, VANPRAAGH AD et al.: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. (2005) 191:2149-2152.
   PubMed Web of Science ®Google Scholar
• DANDEKAR PK, TESSIER PR, WILLIAMS P et al.: Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Chemotherapy (2004) 50:11-16.
   PubMed Web of Science ®Google Scholar
• CHA R, GRUCZ RG Jr, RYBAK MJ: Daptomycin dose-effect relationship against resistant Gram-positive organisms. Antimicrob. Agents Chemother. (2003) 47:1598-1603.
   PubMed Web of Science ®Google Scholar
• LOUIE A, KAW P, LIU W et al.: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. (2001) 45:845-851.
   PubMed Web of Science ®Google Scholar
• DANDEKAR PK, TESSIER PR, WILLIAMS P et al.: Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. (2003) 52:405-411.
   PubMed Web of Science ®Google Scholar
• SAFDAR N, ANDES D, CRAIG WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. (2004) 48:63-68.
   PubMed Web of Science ®Google Scholar
• FLANDROIS JP, FARDEL G, CARRET G: Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob. Agents Chemother. (1988) 32:454-457.
   PubMed Web of Science ®Google Scholar
• VANCE-BRYAN K, LARSON TA, ROTSCHAFER JC et al.: Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (1992) 36:2334-2337.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ, MCKINNON P, CHA R, DVORCHIK BH: Daptomycin Pharmacodynamics (PD) versus MRSA at various doses as assessed by a Monte Carlo prediction model. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2001) A-2195.
   Google Scholar
• LEE BL, SACHDEVA M, CHAMBERS HF: Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. (1991) 35:2505-2508.
   PubMed Web of Science ®Google Scholar
• GARRISON MW, VANCE-BRYAN K, LARSON TA et al.: Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (1990) 34:1925-1931.
   PubMed Web of Science ®Google Scholar
• CRAIG WA, KIEM S, ANDES DR: Effect of protein binding on the antimicrobial activity of daptomycin in sera and albumin solution. Presented at the 42nd Infectious Disease Society of America. Boston (MA) USA (2004) Abstr. 302.
   Google Scholar
• CHA R, RYBAK MJ: Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. (2004) 54:259-262.
   PubMed Web of Science ®Google Scholar
• PANKEY G, ASHCRAFT D, PATEL N: In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob. Agents Chemother. (2005) 49:5166-5168.
   PubMed Web of Science ®Google Scholar
• RAND KH, HOUCK H: Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. (2004) 53:530-532.
   PubMed Web of Science ®Google Scholar
• LECLERCQ R, BINGEN E, SU QH et al.: Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob. Agents Chemother. (1991) 35:92-98.
   PubMed Web of Science ®Google Scholar
• WATANAKUNAKORN C: In-vitro activity of LY 146032, a novel cyclic lipopeptide, alone and in combination with gentamicin or tobramycin against enterococci. J. Antimicrob. Chemother. (1987) 19:445-448.
   Google Scholar
• VAN DER AUWERA P: Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob. Agents Chemother. (1989) 33:1783-1790.
   PubMed Web of Science ®Google Scholar
• TSUJI BT, RYBAK MJ: Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. (2005) 49:2735-2745.
   PubMed Web of Science ®Google Scholar
• RAND KH, HOUCK HJ: Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2004) 48:2871-2875.
   PubMed Web of Science ®Google Scholar
• SCHEETZ M, REDDY P, POSTELNICK M et al.: In vivo synergy of daptomycin plus a penicillin agent for MRSA? J. Antimicrob. Chemother. (2005) 55:398-399.
   PubMedGoogle Scholar
• KING A, PHILLIPS I: The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J. Antimicrob. Chemother. (2001) 48:219-223.
   PubMed Web of Science ®Google Scholar
• BARRY AL, FUCHS PC, BROWN SD: In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. (2001) 45:1919-1922.
   PubMed Web of Science ®Google Scholar
• AKINS RL, RYBAK MJ: In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. (2000) 44:1925-1929.
   PubMed Web of Science ®Google Scholar
• PETERSEN PJ, BRADFORD PA, WEISS WJ et al.: In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46:2595-2601.
   PubMed Web of Science ®Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: Evaluation of daptomycin susceptibility testing by E-test and the effect of different batches of media. J. Antimicrob. Chemother. (2001) 48:557-561.
   Google Scholar
• SADER HS, FRITSCHE TR, JONES RN: Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn. Microbiol. Infect. Dis. (2005) 53:329-332.
   Google Scholar
• STREIT JM, JONES RN, SADER HS: Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J. Antimicrob. Chemother. (2004) 53:669-674.
   PubMed Web of Science ®Google Scholar
• TSUJI BR, CHEUNG CM, AMJAD M: Activity of daptomycin, clindamycin, linezolid, teicoplanin, trimethoprim-sulfamethoxazole and vancomycin against community and hospital associated methicilllin-resistant Staphylococcus aureus. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2005) E-1748.
   Google Scholar
• LAPLANTE KL, RYBAK MJ: Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis. (2004) 50:125-130.
   PubMed Web of Science ®Google Scholar
• WOOTTON MW, TR WALSH, AP MACGOWAN: Daptomycin and vancomycin susceptibilities in vancomycin susceptible Staphylococcus aureus (VSSA) and heterogeneous vancomycin intermediate S. aureus (hVISA) strains. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2005) E-1752.
   Google Scholar
• SAKOULAS G, ALDER J, THAUVIN-ELIOPOULOS C et al.: Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. (2006) 50:1581-1585.
   PubMed Web of Science ®Google Scholar
• CUI L, TOMINAGA E, NEOH HM et al.: Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2006) 50:1079-1082.
   PubMed Web of Science ®Google Scholar
• BOZDOGAN B, ESEL D, WHITENER C et al.: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52:864-868.
   PubMed Web of Science ®Google Scholar
• CHA R, BROWN WJ, RYBAK MJ: Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. (2003) 47:3960-3963.
   PubMed Web of Science ®Google Scholar
• CLINICAL AND LABORATORY STANDARDS INSTITUTE: Performance standards for antimicrobial susceptibility testing. 15th Informational Suppl. M100-S16 (2006).
   Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM CV et al.: Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic Gram-positive species, actinomycetes, and lactobacilli. Antimicrob. Agents Chemother. (2005) 49:408-413.
   PubMed Web of Science ®Google Scholar
• PIPER KE, JACOBSON MJ, STECKELBERG JM, PATEL R: In vitro activity of daptomycin against rare and fastidious Gram-positive organisms Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2005) E-1739.
   Google Scholar
• LIEBOWITZ LD, SAUNDERS J, CHALKLEY LJ et al.: In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide. Antimicrob. Agents Chemother. (1988) 32:24-26.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JA, OLIVER N, ANDREW T et al.: Resistance studies with daptomycin. Antimicrob. Agents Chemother. (2001) 45:1799-1802.
   PubMed Web of Science ®Google Scholar
• LEE BL, CHAMBERS HF, NOVAK RM et al.: Daptomycin versus conventional therapy in the treatment of endocarditis and bacteremia. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago (IL) USA (1991) 885.
   Google Scholar
• LEWIS JS, 2ND, OWENS A, CADENA J et al.: Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. (2005) 49:1664-1665.
   PubMed Web of Science ®Google Scholar
• LONG JK, CHOUEIRI TK, HALL GS et al.: Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin. Proc. (2005) 80:1215-1216.
   PubMed Web of Science ®Google Scholar
• MANGILI A, BICA I, SNYDMAN DR et al.: Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2005) 40:1058-1060.
   PubMed Web of Science ®Google Scholar
• MARTY FM, YEH WW, WENNERSTEN CB et al.: Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. (2006) 44:595-597.
   PubMed Web of Science ®Google Scholar
• HIRSCHWERK D, GINOCCHIO CC, BYTHROW M et al.: diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. (2006) 27:315-317.
   PubMed Web of Science ®Google Scholar
• VIKRAM HR, HAVILL NL, KOETH LM et al.: Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J. Clin. Microbiol. (2005) 43:5384-5387.
   PubMed Web of Science ®Google Scholar
• FOWLER VC, COSGROVE S, ABRUTYN E et al.: Daptomycin versus standard therapy for Staphylococcus aureus bacteremia (SAB) and Infective Endocarditis (SAIE). Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2005) LB-3884.
   Google Scholar
• ARBEIT RD, MAKI D, TALLY FP et al.: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. (2004) 38:1673-1681.
   PubMed Web of Science ®Google Scholar
• LIPSKY BA, STOUTENBURGH U: Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. (2005) 55:240-245.
   PubMed Web of Science ®Google Scholar
• OWENS RC, LAMP KC, RUSSO R et al.: Post marketing experience with daptomycin for the treatment of skin and skin structure infections (SSSI). Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC) USA (2005) L-1573.
   Google Scholar
• CUNHA BA, HAMID N, KESSLER H et al.: Daptomycin cure after cefazolin treatment failure of Methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart Lung (2005) 34:442-447.
   PubMed Web of Science ®Google Scholar
• MOHAN SS, MCDERMOTT BP, CUNHA BA: Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung (2005) 34:69-71.
   PubMed Web of Science ®Google Scholar
• SHAH MM, MURILLO JL: Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin. Ann. Pharmacother. (2005) 39:1741-1743.
   PubMedGoogle Scholar
• SAKOULAS G, RUSSO R, LAMP KC, FRIEDRICH LV: Daptomycin in the treatment of non-catheter related bacteremia (abstract 375). Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco (CA) USA (2005).
   Google Scholar
• LEVINE DP, LAMP KC: Endocarditis treated with daptomycin; experience from a registry (abstract 359). Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco (CA) USA (2005).
   Google Scholar
• ALAM MM, GOYAL B, VINOD G, GO R, JIIMINEZ VE: Daptomycin for treatment of persistent Gram-positive bacteremia and infective endocarditis that failed to respond to currently available agents (abstract 396). Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco (CA) USA (2005).
   Google Scholar
• SEGRETI J, CRANK CW, FINNEY MS: Daptomycin for treatment of drug-resistant Gram-positive bacteremia and infective endocarditis (abstract 425). Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco (CA) USA (2005).
   Google Scholar
• OLESON FB Jr, BERMAN CL, KIRKPATRICK JB et al.: Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother. (2000) 44:2948-2953.
   PubMed Web of Science ®Google Scholar